Sourcing Comparator Drugs for Oncology Clinical Trials

Why sourcing comparator drugs for oncology is uniquely challenging

Oncology is one of the most demanding therapeutic areas for clinical trial supply. Most new cancer drugs are now tested against the existing standard of care, which means almost every oncology study needs reliable comparator drug sourcing. Many of these comparators are high-value biologics that are expensive, in tight supply, and difficult to ship, so a single sourcing gap can put an entire trial behind schedule.

Clinical Services International (CSI) has delivered oncology products to more than 1,200 studies, from generics to the most sophisticated cold chain biologics, supplying medicines to clinical trials across phases I to III. That depth matters in oncology, where protocols, products and timelines are rarely simple.

The oncology comparators sponsors most often need

CSI’s most frequently supplied oncology comparators include pembrolizumab (Keytruda), nivolumab (Opdivo), atezolizumab (Tecentriq), bevacizumab (Avastin), ipilimumab (Yervoy), nab-paclitaxel (Abraxane), palbociclib (Ibrance), rituximab (Mabthera), regorafenib (Stivarga), ruxolitinib (Jakavi), and talazoparib (Talzenna).

Sourcing branded oncology products like these requires direct relationships with manufacturers and authorized distributors so that authenticity, traceability and chain of custody are never in question. The CSI clinical trial supply services are built to secure these products on time and at a competitive price.

Biologics and cold chain: handling temperature-sensitive oncology drugs

A large share of oncology comparators are biologics that must stay within strict temperature limits. CSI provides end-to-end cold and ultra-cold chain logistics at 2 to 8C, -20C, and -80C, using GDP-compliant processes, validated packaging, and qualified couriers, with real-time temperature monitoring and data logging. This temperature-controlled distribution protects product integrity from pickup to the trial site, which is essential when a single excursion can compromise a high-value oncology shipment.

Comedications and combination therapies in oncology

The standard of care in oncology is increasingly a combination of drugs rather than a single agent. Comedications and combination therapies add suppliers, logistics, and timing risk, because each product may need a different source and shipping route. CSI’s scientific team advises on the optimal sourcing strategy for every comedication a protocol requires, factoring in origin of supply, price, expiry and shipment timing, so combination regimens reach sites complete and on schedule.

Biosimilars and generics: balancing cost and protocol fit

Oncology sourcing is not only about branded originators. Where a protocol allows, biosimilars and generics can reduce cost without compromising the study, and CSI can advise on when these are appropriate and how to source them compliantly. The goal is always the same: the right product for the protocol, with the documentation to prove it. The CSI quality and regulatory team certifies products for release and provides the documentation that import, export, and regulators require.

When supply is at risk: rescue sourcing for oncology trials

Even well-planned oncology studies can face shortages, expiring batches, or sudden changes in demand. CSI supports rescue studies where sourcing, compliance, or timelines have gone wrong, and has sourced rescue medications such as ruxolitinib for global studies. A partner that plans for these risks in advance, and can act fast when they appear, protects both the budget and the patients who depend on the trial. You can review related examples in CSI’s oncology case studies.

How to get started

Sourcing oncology comparators well protects your timeline, your budget, and your data. To discuss comparator sourcing for an oncology study with CSI’s scientific team, contact CSI to start the conversation.

Key Takeaways and FAQ

In short, sourcing comparator drugs for oncology trials means handling high-value biologics, cold chain, comedications, and supply risk. A partner with deep oncology experience protects timelines and data. The questions below cover the essentials.

Why is sourcing comparator drugs for oncology trials so difficult?

Most oncology trials test against the standard of care, so they need branded comparators that are often high-value biologics. These products are expensive, in tight supply, and temperature-sensitive, which makes timely and compliant sourcing critical.

Which oncology comparators does CSI commonly supply?

Frequently supplied oncology comparators include pembrolizumab (Keytruda), nivolumab (Opdivo), atezolizumab (Tecentriq), bevacizumab (Avastin), ipilimumab (Yervoy), nab-paclitaxel (Abraxane), palbociclib (Ibrance), rituximab (Mabthera), regorafenib (Stivarga), ruxolitinib (Jakavi), and talazoparib (Talzenna).

How are temperature-sensitive oncology biologics handled?

CSI uses end-to-end cold and ultra-cold chain logistics at 2 to 8C, -20C, and -80C, with GDP-compliant processes, validated packaging, qualified couriers, and real-time temperature monitoring and data logging.